Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Runzao zhiyang capsule (RZZYC) is a traditional Chinese medicine (TCM) herbal formulation developed by Guizhou Tongjitang Pharmaceutical for the treatment of inflammatory skin disorders, including chronic eczema, atopic dermatitis, and plaque psoriasis. Formulated according to TCM theory to 'moisten dryness' (Runzao) and 'relieve itching' (Zhiyang), it is used to alleviate symptoms such as erythema, pruritus, papules, and xeransis. Clinical studies, including Phase 4 trials, have demonstrated its efficacy in reducing Eczema Area and Severity Index (EASI) scores and improving patient quality of life, showing comparable or superior results to some conventional treatments with a favorable safety profile. It is often used as a standalone therapy or in combination with antihistamines like mizolastine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on runzao zhiyang capsule.